This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.4 (acquired coagulation factor deficiency due to liver disease) | Special Copayment Reduction: V311 (severe intractable disease, 5 years) |
| B. Synonyms | Hepatic coagulopathy, coagulopathy of cirrhosis, coagulation factor deficiency related to liver disease, coagulopathy of liver failure, coagulopathy of liver disease |
| C. Adult onset | Possibility of adult onset Very high — liver diseases themselves, such as cirrhosis, acute liver failure, and chronic liver disease, occur mainly in adults (especially in their 40s to 70s), so the related coagulopathy is also concentrated in adults. |
| 1. History | 1950s-60s: hepatocytes identified as the site of coagulation factor synthesis → multifactorial mechanism of cirrhotic coagulopathy elucidated → paradigm shift to rebalancing (2000s) → introduction of individualized transfusion strategies based on ROTEM/TEG. |
| 2. Causes | Cirrhosis (alcoholic, viral, nonalcoholic), acute liver failure (viral, drug-induced, ischemic), cholestasis (decreased vitamin K absorption), DIC accompanying sepsis, during liver transplant surgery. |
| 3. Genetics | Not a direct genetic disease; the genetic background of the underlying liver disease causes (Wilson disease ATP7B, alpha-1 antitrypsin deficiency SERPINA1, hereditary hemochromatosis HFE, etc.) is involved in liver disease progression. |
| 4. General epidemiology | Cirrhosis prevalence about 0.3-0.5% (developed countries); prolonged PT/INR is very common in cirrhosis patients; incidence of esophageal variceal bleeding in cirrhosis patients 5-15% per year. |
| 5. Pathophysiology | Decreased coagulation factor synthesis + concomitant decrease in anticoagulant proteins (rebalancing) + hyperfibrinolysis + dysfibrinogenemia + thrombocytopenia (hypersplenism, decreased TPO) + possible coexisting DIC. |
| 6. Symptoms | Esophageal and gastric variceal bleeding (hematemesis, melena), intra-abdominal bleeding, ecchymosis, epistaxis, gum bleeding, excessive bleeding after surgery or procedures, accompanied by spontaneous bacterial peritonitis. |
| 7. Signs | Prolonged PT/INR, thrombocytopenia, decreased fibrinogen (in advanced disease), dysfibrinogenemia, jaundice, ascites, splenomegaly, spider angiomas. |
| 8. Screening | Regular PT/INR, platelet, and fibrinogen monitoring in cirrhosis patients; coagulation assessment before invasive procedures; INR is included in MELD score calculation. |
| 9. Diagnosis | PT, APTT, fibrinogen, D-dimer, platelets; individual coagulation factor activity (FV, FVII, etc.); ROTEM/TEG viscoelastic testing; confirmation of response after vitamin K administration (differentiation from vitamin K deficiency); liver function tests. |
| 10. Treatment | Treatment of underlying liver disease (alcohol abstinence, antivirals, liver transplantation); in acute bleeding, FFP, platelets, fibrinogen concentrate, 4F-PCC, rFVIIa; ROTEM/TEG-guided transfusion; tranexamic acid (in hyperfibrinolysis). |
| 11. Prognosis | Depends on the severity of the underlying liver disease; coagulation recovers with successful liver transplantation; elevated INR in acute liver failure is an indicator of poor prognosis; high risk of recurrent variceal bleeding. |
| 12. Prevention | Management of the cause of liver disease (alcohol abstinence, treatment of viral hepatitis); primary prevention of variceal bleeding (nonselective beta-blockers, EVL); correction of coagulation before procedures. |
| 13. References | Tripodi A et al. NEJM 2011 and 9 other papers |
Hemostatic abnormalities accompanying liver disease have long been observed clinically, but understanding of their mechanisms was achieved systematically only after the mid-20th century. Clinical observations that bleeding tendency increases in cirrhosis patients were reported in the late 19th century, but the scientific foundation to explain this was laid only when knowledge of coagulation proteins was established.
Over the 1950s-60s, it was experimentally confirmed that hepatocytes are the main site of synthesis of most coagulation factors, including fibrinogen (FI), prothrombin (FII), and factors V, VII, IX, and X. After the vitamin K-dependent coagulation factors (FII, FVII, FIX, FX) were established in the 1960s, it became clear that PT prolongation in liver disease results not only from vitamin K deficiency but also from multifactorial coagulation factor deficiency due to reduced hepatocyte synthetic capacity. In the same period, the prothrombin time (PT) became established as a simple indicator of liver function.
In the 1970s-80s, it was confirmed that hyperfibrinolysis accompanies cirrhosis, which was explained by decreased hepatic clearance of tissue plasminogen activator (tPA) and decreased α2-antiplasmin (α2-AP). Dysfibrinogenemia was also identified in cirrhosis, and a phenomenon in which the fibrinogen amount is normal but its function is reduced was reported. In the 1990s, the liver was shown to be the main site of thrombopoietin (TPO) synthesis, confirming that decreased TPO production is one of the important mechanisms of thrombocytopenia in cirrhosis.
In the 2000s the most important paradigm shift occurred. Lisman et al. argued that because anticoagulant proteins (protein C, S, antithrombin) also decrease together with coagulation factors in cirrhosis patients, evaluating bleeding risk in cirrhosis patients by PT/INR alone is insufficient. This is called the "rebalancing" concept, and it became the key theory explaining the discrepancy between in vitro coagulation test results and clinical bleeding risk. This concept fundamentally questioned the practice of indiscriminate fresh frozen plasma (FFP) transfusion based only on prolonged PT/INR in cirrhosis patients.
Recently, evidence has accumulated that viscoelastic tests (TEG, ROTEM), which assess whole blood coagulation in real time, reflect actual bleeding risk more accurately in liver disease patients. In the 2019 American Gastroenterological Association guideline, an individualized strategy using ROTEM/TEG for transfusion decisions before procedures in cirrhosis patients began to be recommended. In liver transplantation as well, ROTEM-guided transfusion has been shown to markedly reduce intraoperative use of blood products.
The cause of coagulation factor deficiency due to liver disease is determined by the type and severity of the underlying liver disease.
Alcoholic cirrhosis is one of the most common causes of cirrhosis in Korea and abroad, and coagulation factor deficiency is worsened by the combined action of hepatocyte injury from the direct toxicity of alcohol and vitamin K deficiency from malnutrition. Cirrhosis due to viral hepatitis (hepatitis B and C) is the most important cause in Korea, and coagulation factor synthetic capacity decreases gradually with progression of hepatocyte inflammation and fibrosis. Cirrhosis due to nonalcoholic steatohepatitis (NASH) is also increasing. Autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Wilson disease, alpha-1 antitrypsin deficiency, and hereditary hemochromatosis can also progress to cirrhosis and cause coagulopathy.
Acute liver failure is a condition in which abrupt hepatocellular necrosis occurs in a previously healthy person and hepatic encephalopathy and coagulopathy appear within weeks. Causes include drug toxicity (acetaminophen overdose is the most common cause; isoniazid, valproic acid, etc.), acute viral hepatitis (hepatitis A and B, HSV, EBV), ischemic hepatitis (hypotension, right heart failure), autoimmune hepatitis, acute presentation of Wilson disease, and Budd-Chiari syndrome. In ALF, coagulation factor deficiency progresses very rapidly, and elevated PT/INR is included in the diagnostic criteria.
In cholestasis, bile acid secretion into the small intestine decreases, reducing absorption of fat-soluble vitamin K. This causes deficiency of the vitamin K-dependent coagulation factors (FII, FVII, FIX, FX), which is corrected quickly with vitamin K administration. Causes of obstructive jaundice include common bile duct stones, pancreatic head cancer, cholangiocarcinoma, and bile duct stricture.
When ischemic hepatitis due to sepsis (shock liver) or DIC coexists with liver disease, coagulopathy is worsened. During liver transplant surgery, coagulation factors are rapidly consumed in the process of hepatectomy and reperfusion, and hyperfibrinolysis is aggravated.
Coagulation factor deficiency due to liver disease is not a directly hereditary disease, and a genetic defect in coagulation factor synthesis itself is not the cause. However, there are several hereditary diseases that cause liver disease, and understanding them is important for identifying the underlying cause of coagulopathy.
Wilson disease: Abnormal copper metabolism due to ATP7B gene (13q14.3) mutations causes copper accumulation in the liver, leading to cirrhosis and acute liver failure, accompanied by severe coagulopathy together with Coombs-negative hemolytic anemia. Alpha-1 antitrypsin deficiency: homozygosity (ZZ) for the Z allele of the SERPINA1 gene (14q32.13) → accumulation of abnormal protein in the liver → cirrhosis → coagulopathy. Hereditary hemochromatosis: iron overload due to homozygosity for the C282Y variant of the HFE gene (6p22.2) → cirrhosis. CFTR gene variants (cystic fibrosis): progression to cholestatic cirrhosis, decreased vitamin K absorption → coagulopathy. In patients with such hereditary liver diseases, early genetic diagnosis and monitoring of liver disease progression are also important for preventing coagulopathy.
Polymorphisms in genes involved in coagulation factor synthesis (GGCX, gamma-carboxylase, etc.) may contribute to the severity of coagulation factor deficiency in liver disease patients, but research on this is still at an early stage. VKORC1 and CYP2C9 polymorphisms, in relation to vitamin K metabolism, play a partial role in determining individual differences in correction of coagulation factors in liver disease patients.
The precise prevalence of coagulation factor deficiency due to liver disease increases in proportion to the severity of the underlying liver disease. Cirrhosis is estimated to affect more than 100 million people worldwide and causes about 1.1 million deaths per year. In Korea, the prevalence of hepatitis B, a major cause of cirrhosis, is high at about 3-4% of adults, so cirrhosis-related coagulopathy is an important clinical problem.
Prolonged PT/INR is observed in about 60-70% of cirrhosis patients, and in severe cirrhosis (Child-Pugh class C) abnormal coagulation findings appear in nearly all patients. Thrombocytopenia (less than 50,000/μL) occurs in about 30-40% of cirrhosis patients. In acute liver failure patients, elevated PT/INR appears in nearly all patients at admission, and it is included in the diagnostic criteria (PT >15 seconds or INR >1.5).
Esophageal and gastric variceal bleeding occurs in about 5-15% per year in cirrhosis patients, and when bleeding occurs, mortality within 6 weeks is about 15-20%. Procedure-related bleeding (paracentesis, transjugular intrahepatic portosystemic shunt, liver biopsy, etc.) is also an important complication. In Korean Association for the Study of the Liver statistics, the annual incidence of bleeding complications in cirrhosis patients is reported as about 5-10%.
Coagulopathy in liver disease is understood not as simple coagulation factor deficiency but as a complex and dynamic hemostatic imbalance. The key concept is that procoagulant proteins and anticoagulant proteins decrease simultaneously, so an apparently "rebalanced" state is maintained, but this balance can easily tip toward bleeding or thrombosis.
Hepatocytes synthesize vitamin K-dependent factors (FII, FVII, FIX, FX, protein C, S, Z) and vitamin K-independent factors (FV, excluding FVIII, fibrinogen, factors XI and XII, antithrombin, α2-antiplasmin). When hepatocyte function is impaired, synthesis of these factors decreases overall. FVII has the shortest half-life, 4-6 hours, so it declines earliest when liver function declines, and this is the early cause of PT prolongation. FVIII is synthesized in endothelial cells as well as hepatocytes, so it tends to remain relatively high or even increase in cirrhosis (along with elevated vWF).
Because protein C, S, antithrombin (AT), and tissue factor pathway inhibitor (TFPI) are all synthesized in the liver, anticoagulant proteins also decrease along with the decrease in coagulation factors. For this reason, decreased prothrombin activity measured by PT/INR does not necessarily imply bleeding tendency. In fact, in cirrhosis patients, thrombin generation capacity (calibrated automated thrombography, CAT) is observed to be near normal or even increased. This is the core of the rebalancing concept.
Thrombocytopenia in cirrhosis arises from ① platelet sequestration due to splenomegaly (hypersplenism), ② decreased platelet production due to decreased TPO synthesis, and ③ immune-mediated platelet destruction (hepatitis-related antiplatelet antibodies). However, because vWF concentration and activity are markedly elevated in cirrhosis and compensate platelet adhesion and aggregation, the clinical significance of a reduced platelet count varies by situation.
Decreased hepatic clearance of tissue plasminogen activator (tPA) → elevated blood tPA, decreased synthesis of α2-antiplasmin, and decreased plasminogen activator inhibitor (PAI-1) combine to produce a tendency toward hyperfibrinolysis. This can be confirmed on ROTEM by shortened fibrin clot lysis times (LI30, LI60). Hyperfibrinolysis is especially marked during liver transplant surgery, in acute liver failure, and in end-stage cirrhosis.
In cirrhosis, increased sialic acid content of the fibrinogen molecule interferes with polymerization of fibrin monomers, so fibrin clot formation becomes incomplete. This is called dysfibrinogenemia and is reflected in prolonged TT (thrombin time).
The clinical bleeding symptoms of coagulation factor deficiency due to liver disease vary according to the severity of the underlying liver disease and the nature of the specific coagulation abnormality.
Varix formation due to portal hypertension is the most dangerous cause of bleeding in cirrhosis. It presents as sudden massive hematemesis or melena or hematochezia and may be accompanied by hypovolemic shock. In this case the bleeding is not a problem of coagulopathy alone but the combined result of variceal rupture and coagulation abnormality. When bleeding occurs, complex complications accompany it, such as bacterial infection (risk of spontaneous bacterial peritonitis), induction of hepatic encephalopathy, and worsening renal failure.
Spontaneous intra-abdominal bleeding is rare but fatal when it occurs. Skin and mucosal bleeding (ecchymosis, gum bleeding, epistaxis) is commonly observed in cirrhosis. Excessive bleeding after invasive procedures such as dental extraction, endoscopic biopsy, paracentesis, liver biopsy, and laparoscopic surgery is a problem.
In acute liver failure, coagulation factors are lost rapidly, and intracranial hemorrhage (together with cerebral edema) is an important cause of death. Gastrointestinal bleeding and urinary tract bleeding can also occur. Coagulopathy in acute liver failure is highly dynamic and requires daily or more frequent monitoring.
According to the rebalancing concept, cirrhosis patients have an increased risk of thrombosis as well as bleeding. Portal vein thrombosis (PVT), deep vein thrombosis (DVT), and pulmonary embolism are increased in cirrhosis patients compared with the general population, owing to decreased anticoagulant proteins and reduced venous flow.
On physical examination, signs of chronic cirrhosis are identified, such as jaundice (skin and sclera), ascites (abdominal distension, shifting dullness), splenomegaly, spider angiomata, palmar erythema, feminized breasts in men (gynecomastia), and muscle weakness. Bleeding-related physical findings that may be observed include skin petechiae, extensive ecchymosis, oral mucosal bleeding, and scleral hemorrhage.
On laboratory findings, prolonged PT/INR is the most characteristic, and INR >2.0 is common in severe cirrhosis (Child-Pugh C). Thrombocytopenia (<150,000/μL, often <80,000/μL) accompanies it. APTT varies more than PT, and when both tests are prolonged it suggests deficiency of common pathway factors. Fibrinogen is mostly normal but decreases in end-stage cirrhosis or with complicating DIC. In dysfibrinogenemia, thrombin time (TT) is prolonged. FV activity is a sensitive indicator of liver function; FV <25% reflects the severity of acute liver failure and is used to judge the indication for liver transplantation (Clichy criteria). Elevated D-dimer suggests DIC or hyperfibrinolysis. On ROTEM/TEG, prolonged clot formation time, decreased maximum clot firmness (MCF), and increased early fibrinolysis are identified.
In cirrhosis patients, regular assessment of coagulation status is essential for monitoring bleeding risk and planning invasive procedures. At outpatient follow-up, basic blood tests including PT/INR and platelet count are performed every 3-6 months. The Child-Pugh or MELD score is used to comprehensively evaluate liver function and coagulation status, and INR is included in the MELD score calculation. Before invasive procedures (liver biopsy, paracentesis, sclerotherapy, portal vein angioplasty, etc.), coagulation assessment including PT/INR, platelets, and fibrinogen is performed, and ROTEM/TEG is added when necessary. In acute liver failure patients, coagulation tests are performed immediately at admission and at least once daily thereafter, and monitored more often if the condition worsens. In patients waiting for liver transplantation, the MELD score (INR, bilirubin, creatinine) is calculated regularly to determine transplant priority.
Diagnosis of coagulation factor deficiency due to liver disease consists of confirming the underlying liver disease, characterizing the coagulation abnormality, and excluding other causes.
Standard coagulation tests: PT/INR, APTT, thrombin time (TT), fibrinogen (Clauss method), D-dimer, platelet count. In cirrhosis PT/INR is typically prolonged, but in liver disease PT/INR may overstate the actual bleeding risk. To differentiate from vitamin K deficiency, the change in PT/INR 24 hours after vitamin K₁ 10 mg administration is checked (correction of 50% or more after vitamin K administration makes vitamin K deficiency likely). Individual coagulation factor activity: Measurement of FV activity is a sensitive indicator of liver function and, being vitamin K-independent, is useful for differentiating from vitamin K deficiency. FVII activity (short half-life, early decrease), and FII and FX activity are also measured. FVIII tends to be normal to elevated in liver disease, so if FVIII is decreased, DIC or another cause is suspected. Viscoelastic tests (ROTEM/TEG): clot formation time, maximum firmness, and degree of fibrinolysis are evaluated together. In cirrhosis patients, actual coagulation capacity on ROTEM reflects clinical bleeding risk better than PT/INR. Evaluation of underlying liver disease: liver function tests (ALT, AST, ALP, GGT, bilirubin, albumin), liver ultrasound/CT, and evaluation of cirrhosis-related complications (ascites, varices, splenomegaly). Differentiation of the cause (hepatitis B and C, alcohol, autoimmune hepatitis, Wilson disease, etc.).
Treatment of coagulopathy due to liver disease is divided into ① treatment of the cause of the underlying liver disease, ② hemostatic management of acute bleeding, and ③ prophylactic correction of coagulation before procedures.
Alcoholic cirrhosis: Complete abstinence from alcohol is the most important for liver recovery and improvement of coagulation function. Viral cirrhosis: viral suppression with hepatitis B antivirals (entecavir, tenofovir), and partial recovery of liver function is possible with cure by hepatitis C DAAs (direct-acting antivirals). Liver transplantation is the definitive treatment that completely restores coagulation function in end-stage liver disease.
When prolonged PT is identified in a cirrhosis patient, vitamin K₁ (5-10 mg intravenously or orally) is given as a trial to check for correction. If there is correction, it suggests a vitamin K deficiency component; if there is no correction, the coagulation factor deficiency is due purely to decreased hepatocyte synthesis.
Variceal bleeding: endoscopic variceal ligation (EVL) or endoscopic sclerotherapy, vasoconstrictors (terlipressin, octreotide), prophylactic antibiotics (norfloxacin or ceftriaxone). For correction of coagulation, fresh frozen plasma (FFP), platelet transfusion, and fibrinogen concentrate (or cryoprecipitate) are used under ROTEM/TEG guidance. Indiscriminate administration of FFP based on PT/INR alone is avoided because of the risk of volume overload and TACO (transfusion-associated circulatory overload). Four-factor PCC (prothrombin complex concentrate, 4F-PCC) allows rapid correction of PT with a smaller volume than FFP and can replace coagulation factors without excessive fluid infusion. In hyperfibrinolysis: tranexamic acid (TXA) 1 g intravenously or ε-aminocaproic acid. Platelet transfusion for platelets <50,000/μL or active bleeding. TPO receptor agonists (eltrombopag, avatrombopag) can be used to raise platelets before procedures in cirrhosis.
Coagulation correction is individualized under ROTEM/TEG guidance. The direction of the latest guidelines is not to make pre-procedure transfusion decisions on PT/INR alone. Platelet transfusion is considered before high-risk procedures (liver biopsy, etc.) at platelets <50,000/μL. Administration of fibrinogen concentrate or cryoprecipitate is considered at fibrinogen <1.5 g/L.
The prognosis of coagulation factor deficiency due to liver disease is directly tied to the course of the underlying liver disease. In acute liver failure, the degree of INR elevation directly reflects prognosis; the King's College criteria for transplantation in non-acetaminophen liver failure include PT >100 seconds (or INR >6.5) or any 3 of the following: age <10 or >40 years, interval from jaundice to onset of encephalopathy >7 days, PT >50 seconds, bilirubin >300 μmol/L. If liver transplantation is successful, the ability of the new liver to synthesize coagulation factors is restored and coagulation function normalizes. In chronic cirrhosis, bleeding complications (variceal bleeding, intra-abdominal bleeding) are a leading cause of cirrhosis-related death, with a 6-week mortality of about 15–20%. In alcoholic cirrhosis, coagulation function may also improve when liver function partially recovers with complete abstinence from alcohol. In viral cirrhosis, coagulation factor levels may improve in some cases once liver fibrosis is reversed to some degree after successful antiviral treatment.
The key to preventing coagulopathy due to liver disease is to halt progression to cirrhosis. Prevention of viral hepatitis: prevent progression to cirrhosis through expanded hepatitis B vaccination and early antiviral treatment, and early detection of hepatitis C with DAA treatment. Alcohol abstinence: keep alcohol intake to 14 units or less per week for men and 7 units or less for women; participation in abstinence support programs for patients with alcohol dependence. Management of metabolic syndrome: weight control to prevent NASH, and active treatment of diabetes and dyslipidemia. Primary prevention of variceal bleeding: when endoscopy in a cirrhosis patient shows esophageal varices of moderate or greater size, prevent the first bleeding with a non-selective beta-blocker (propranolol, nadolol, carvedilol) or endoscopic variceal ligation (EVL). Pre-procedure education and preparation: before invasive procedures in cirrhosis patients, consult hematology or hepatology to assess bleeding risk in advance and establish appropriate preventive measures. Nutritional support: adequate nutritional intake to prevent vitamin K deficiency in cirrhosis patients, with supplements as needed.